Since it is a new treatment method, the effect is quite good. Foreign companies’ scientific institutions invest a lot of money in the process of cancer immunotherapy, and nowadays tumor immunotherapy is still very expensive. Take PD-1 antibody as an example, it costs more than 30,000 yuan to apply PD-1 antibody in our country for a month, and 300,000-400,000 yuan for a year, such a cost is difficult for general families to afford. But fortunately for PD-1 antibodies, there are many original drugs in China, currently there are about 7 or 8 kinds of PD-1 antibody drugs in China, which will be listed in the short term. Once these original drugs are listed, foreign imported PD-1 antibodies will follow the price reduction to a certain extent and may enter the medical insurance, and after entering the medical insurance, more oncology patients can be benefited. Therefore, immunotherapy is very expensive in a short period of time, but about 2-3 years later, it is estimated that the price will be reduced to a price that most patients can accept, and even enter the medical insurance, so that more Chinese patients can use these new treatments with good efficacy and low side effects.